Blautia wexlerae was isolated from human faeces.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Product Information | |
---|---|
Product Overview | Blautia wexlerae was isolated from human faeces. |
Target | Blautia |
Genus | Blautia |
Strain Designation | Walcc: 14507 |
Application | Study and research |
Type Strain | Yes |
Culture Medium | Chocolate agar |
Culture Conditions | 37°C; Anaerobic |
Source | Human feces |
Risk Group | 1 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Blautia is a genus of anaerobic bacteria with probiotic characteristics that occur widely in the feces and intestines of mammals. |
Alternative Names | Blautia wexlerae; |
To prepare Blautia wexlerae; BAA-1564 inoculum, reconstitute the freeze-dried culture in an anaerobic medium. Incubate at 37°C until it reaches the desired optical density. Standardize the inoculum concentration using serial dilutions or spectrophotometric methods.
In microbial interaction studies, Blautia wexlerae; BAA-1564 can be co-cultured with other gut bacteria. Monitoring interactions through colony counts, metabolic assays, and molecular techniques helps understand its role in the microbial community.
Blautia wexlerae; BAA-1564 can be employed to investigate the mechanisms of antibiotic resistance within the gut microbiome. Researchers can expose the strain to various antibiotics and analyze genetic and phenotypic changes. This helps in understanding how gut bacteria develop resistance and the potential impact on human health.
The genome of Blautia wexlerae; BAA-1564 contains genes involved in carbohydrate metabolism, stress response, and antibiotic resistance. Sequencing the genome provides insights into its metabolic capabilities, interactions with the host, and potential as a probiotic. Researchers often focus on these features to explore therapeutic applications.
One of the main challenges is maintaining strict anaerobic conditions required for its growth. Additionally, there may be difficulties in isolating and culturing this strain from complex samples. Researchers must also consider the potential for contamination and ensure accurate identification of the strain in mixed cultures.
High-fat diet (HFD)-induced obesity and diabetes were ameliorated by oral administration of Blautia wexlerae to mice
The study explores the impact of Blautia wexlerae on obesity and type 2 diabetes, particularly focusing on its metabolic effects when administered orally. The research identifies B. wexlerae as inversely correlated with obesity and type 2 diabetes in Japanese adults. Experimental data from mouse models reveal that oral supplementation with B. wexlerae significantly reduced high-fat diet-induced obesity and diabetes. This effect is attributed to metabolic remodeling, which includes the production of metabolites such as S-adenosylmethionine, acetylcholine, and L-ornithine. These metabolites contribute to anti-inflammatory and anti-adipogenic processes, altering the gut microbiota composition. The significance of this research lies in the potential therapeutic applications of B. wexlerae in managing metabolic disorders. By modulating gut microbiota and metabolic pathways, B. wexlerae offers a novel approach to preventing and treating obesity and type 2 diabetes. The findings highlight the broader implications of gut microbiota in human health, paving the way for developing probiotic-based treatments targeting metabolic diseases.
Hosomi, Koji, et al. "Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota." Nature communications 13.1 (2022): 4477.
Under open access license CC BY 4.0, without modification.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.